Title of Invention: Aryl-cyanoguanidine compounds Abstract: The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine-pyrazolines of general formula (I) wherein R1, R2, R3, R4, R5, X and r have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyper-proliferative disorders, in particular for cancer, respectively tumor disorders. The present invention furthermore relates to the use of SMYD2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility. Detailed Description: Part general_description_paragraphs: Part CROSS REFERENCE TO RELATED APPLICATIONS: This application is the national stage of International Application No. PCT/EP2015/078912, filed internationally on Dec. 8, 2015, which claims the benefit of European Application Nos. 14196766.1, filed Dec. 8, 2014, and 15163993.7, filed Apr. 17, 2015, the disclosures of which are hereby incorporated by reference in their entireties for all purposes. Part SUBMISSION OF SEQUENCE LISTING ON ASCII TEXT FILE: The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 777052015900seqlisting.txt, date recorded: Jun. 7, 2017, size: 9 KB). The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine-pyrazolines, to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyperproliferative disorders, in particular for cancer, respectively tumour disorders. The present invention furthermore relates to the use of SMYD2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility. Part BACKGROUND: Post-translational modifications (PTMs) of histone proteins, such as acetylation, methylation, phosphorylation, and ubiquitylation, play essential roles in regulating chromatin dynamics and gene expression (Jenuwein and Allis, Science, 2001, 293(5532):1074-80). Combinations of different modifications on histone proteins, termed the ‘histone code’, extend the information potential and regulate the readout of the genetic code. In addition to histones it has been found that many PTMs occur on non-histone proteins. These PTMs regulate protein-protein interactions, stability, localization, and/or enzymatic activities of proteins (Sims and Reinberg, Nat Rev Mol Cell Biol., 2008, 9:815-20). Therefore PTMs on non-histone proteins (e.g. on transcription factors) can substantially alter protein function, extending the regulatory role of PTMs to multiple cellular pathways (Benayoun and Veitia, Trends Cell Biol., 2009, 19(5):189-97). Along with serine, threonine and tyrosine phosphorylation, lysine methylation also plays a critical role in cell function (Huang and Berger, Curr Opin Genet Dev, 2008, 18(2):152-8). The enzymes responsible for lysine methylation were initially found to target histones. Accumulating evidence confirmed that some of these enzymes are not completely histone specific, but rather have a broader spectrum of protein substrates and are therefore termed protein lysine methyltransferases (PKMTs) (Lanouette et al., Mol Syst Biol., 2014, 10:724). Misregulation of PKMTs has been reported in cancer cell lines as well as in cancer patients (Miremadi et al., Hum Mol Genet., 2007, 16 Spec No 1:R28-49; Kudithipudi and Jeltsch, Biochim Biophys Acta, 2014, 1846(2):366-379) Accordingly, lysine was shown to influence different pathways directly linked to oncogenic transformation, providing a rationale for the involvement of PKMTs in cancer and for developing inhibitors for therapeutic intervention (Mair et al., Trends Pharmacol Sci., 2014, 35(3):136-45; Wagner and Jung, Nat Biotechnol., 2012, 30(7):622-3). In the present invention, inhibitors directed against the PKMT SET and MYND domain-containing protein 2 (SMYD2) are described. SMYD2 is a catalytic SET domain containing protein methyltransferase reported to monomethylate several lysine residues on histone and non-histone proteins. Initially SMYD2 was characterized to methylate H3 lysine 36 (Brown et al., Mol Cancer., 2006, 5:26) and lysine 4 when interacting with HSP90a (Abu-Farha et al., Mol Cell Proteomics, 2008, 7(3):560-722008). Methylation of histones by SMYD2 has been connected to increased transcription of genes involved in cell cycle regulation, chromatin remodeling, and transcriptional regulation (Abu-Farha et al., Mol Cell Proteomics, 2008, 7(3):560-722008). In addition to the function of SMYD2 in transcriptional regulation, several studies uncovered an important role of SMYD2 methylation activity on non-histone proteins closely connected to cancer. For example, the p53 tumor suppressor gene is mutated in approximately 50% of human cancers and protein activity is frequently repressed in the non-mutated cases, indicating a central role of p53 in preventing tumorgenesis (Levine, Cell, 1997, 88(3):323-31). It has been demonstrated that the activity of p53 protein is inhibited by SMYD2 mediated posttranslational methylation at lysine 370 (K370) (Wu et al., Biochemistry, 2011, 50(29):6488-97; Huang et al., Nature, 2006, 444(7119):629-32;). The structural basis of p53 methylation by SMYD2 has been characterized by solving the crystal structure of a ternary complex with cofactor product S-adenosylhomocysteine and a p53 substrate peptide (Wang et al., J Biol Chem., 2011, 286(44):38725-37). Methylation at K370 reduces the DNA-binding efficiency of p53 and subsequently prevents the transcriptional activation of the tumor suppressive genes p21 and MDM2 (Huang et al., Nature, 2006, 444(7119):629-32). In the same study, a knockdown of SMYD2 and treatment with doxorubicin led to an increase in p53-mediated cell-cycle arrest and apoptosis in a cancer cell line model. In line with these observations, low SMYD2 gene expression was suggested as predictive marker of an improved response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in breast cancer patients (Barros Filho et al., Braz J Med Biol Res., 2010, 43(12):1225-31). Additionally, a regulatory role of SMYD2 on p53 activity was confirmed independently in heart biology. SMYD2 was characterized in a cardiomyocyte model to be a cardioprotective protein by methylating p53, thereby reducing p53 mediated apoptosis induction (Sajjad et al., Biochim Biophys Acta., 2014, 1843(11):2556-62). Therefore SMYD2 inhibitors may provide new therapeutic options for cancers with SMYD2-mediated inactivation of the p53 tumor suppressor. Another study revealed an additional link to cancer chemotherapy by uncovering the SMYD2-dependent methylation of poly(ADP-Ribose) Polymerase-1 (PARP1). Methylation of PARP1 at lysine 528 (K528) positively regulated the poly(ADP-ribosyl)ation activity of oncogenic protein PARP1 in cancer cells (Piao et al., Neoplasia, 2014, 16(3):257-64). PARP1 is involved in the base excision pathway of DNA repair. Increased PARP1 activity is known as possible escape mechanism from apoptosis induction by DNA-damaging agents for cancer cells (Peralta-Leal et al., Clin Transl Oncol., 2008, 10(6):318-23). Knockdown of SMYD2 resulted in the reduction of PARP1 enzymatic activity, suggesting that SMYD2 inhibition could improve cancer chemotherapy efficacy (Piao et al., Neoplasia, 2014, 16(3):257-64). The retinoblastoma protein (Rb) is a further important tumor suppressor protein regulated by SMYD2. Rb normally restricts DNA replication by preventing the progression from G1 to the replicative S phase of the cell division cycle, by binding to and inhibiting transcription factors of the E2F family (Weinberg, Cell, 1995, 81(3):323-30). SMYD2 methylates Rb at lysine 810 (K810) and 860 (K860). SMYD2 methylation of K810 enhances phosphorylation of Rb and its dissociation from E2F, which promotes abnormal cell cycle progression to S phase and proliferation in cancer (Cho et al., Neoplasia, 2012, 14(6):476-86) In line with these observations, it has been shown that knockdown of SMYD2 in an esophageal squamous cell carcinoma (ESCC) cell line overexpressing SMYD2 led to suppression of proliferation due to G1 arrest (Komatsu et al., Carcinogenesis, 2009, 30(7):1139-46). The HSP90 chaperone is another protein regulated by SMYD2. This protein is a crucial facilitator of oncogene addiction and cancer survival (Whitesell et al., Nat Rev Cancer., 2005, 5(10):761-72). Cancer cells are dependent on the HSP90 chaperone machinery to protect oncoproteins from misfolding and degradation. In a protein-protein interaction study, SMYD2 was identified as an interaction partner of HSP90 (Abu-Farha et al., J Mol Cell Biol., 2011, 3(5):301-8). Different studies revealed multiple sites of SMYD2 dependent HSP90 methylation at lysines 531 (K531) and 574 (K574) (Hamamoto et al., Cancer Lett., 2014, 351(1):126-33) and lysines K209 and K615 (Abu-Farha et al., J Mol Cell Biol., 2011, 3(5):301-8). Methylation was shown to be important for dimerization and chaperone complex stability. Initially HSP90 regulation by SMYD2 was described in normal muscle tissue maintenance (Donlin et al., Genes Dev., 2012, 26(2):114-9; Voelkel et al., Biochim Biophys Acta. 2013, 1833(4):812-22). Notably, an additional role of HSP90 methylation by SMYD2 in human carcinogenesis was reported (Hamamoto et al., Cancer Lett., 2014, 351(1):126-33). Knockdown of SMYD2 in cancer cell lines destabilized ERBB2 and CDK4 oncoproteins, and overexpression of methylated HSP90 accelerated proliferation of model cell lines indicating an additional cancer promoting role of SMYD2. In the MCF7 breast cancer model it has been demonstrated that SMYD2-mediates estrogen receptor alpha (ERα) methylation at lysine 266 (K266). SMYD2 thereby also has a potential role in breast cancer by fine-tuning the functions of ERα and estrogen induced gene expression (Zhang et al., Proc Natl Acad Sci USA., 2013, 110(43):17284-9; Jiang et al., J Mol Biol. 2014, 426(20):3413-25). In cancers, several studies detected abnormally high expression of SMYD2. In a model of aggressive acute myeloid leukemia (AML) containing the MLL-AF9 fusion oncoprotein, SMYD2 expression was identified as part of a program of aberrant self-renewal genes linked to leukemia stem cells and poor prognosis (Zuber et al., Genes Dev., 2011, 25: 1628-1640). Different studies reported overexpression of SMYD2 in cancer cell lines as well as in ESCC, bladder carcinoma, gastric cancer and pediatric acute lymphoblastic leukemia patients (Komatsu et al., Carcinogenesis, 2009, 30(7):1139-46 and Br J Cancer, 2014, doi: 10.1038/bjc.2014.543; Cho et al., Neoplasia, 2012, 14(6):476-86; Sakamoto et al, 2014, 38(4):496-502). Notably higher SMYD2 expression in ESCC, gastric cancer, and acute lymphoblastic leukemia patients correlated with lower survival rate and was suggested to be a clinically relevant prognostic marker, further indicating an oncogenic role of SMYD2 (Komatsu et al., Carcinogenesis, 2009, 30(7):1139-46 and Br J Cancer, 2014, doi: 10.1038/bjc.2014.543; Sakamoto et al., Leuk Res., 2014, 38(4):496-502). In validation experiments in these reports, knockdown of SMYD2 in overexpressing ESCC, bladder and gastric cancer cell line models significantly reduced cell proliferation. One potential underlying explanation for higher SMYD2 expression in cancer patients was described for ESCC. The SMYD2 gene is localized in a genomic region around 1q32 q41 which has been found to be frequently amplified in ESCC cell lines and patients (Komatsu et al., Carcinogenesis, 2009, 30(7):1139-46; Pimkhaokham et al., Jpn J Cancer Res., 2000, 91(11):1126-33). These studies indicate that the SMYD2 proteins play an essential role in various pathologies. It would therefore be desirable to find potent and selective inhibitors which prevent the SMYD2 methylation activity. Part PRIOR ART: WO 2006/072350 discloses cyanoguanidine-substituted pyrazolines and the use of such compounds as medicaments related to the field of blood coagulation. The examples of this application consist only of 3-(4-chlorophenyl)-4,5-dihydro-1H-pyrazoles, which are only weak SMYD2 inhibitors. There is no specific example which is covered by the formula (I) as described and defined herein. WO 2005/007157 discloses pyrazolines as PAR-1 antagonists for treatment of cardiovascular diseases. However, the specific examples disclosed in WO 2005/007157 are not covered by the formula (I) as described and defined herein. WO 1991/11438 discloses arthropodicidal pyrazolines. The claimed 4,5-dihydro-1H-pyrazoles may be substituted in the 4-position, but not with a nitrogen atom at this position. The specific examples disclosed in WO 1991/11438 are not covered by the formula (I) as described and defined herein. Based on the chemical structure, only very few types of Smyd 2 inhibitors have been described to date. Ferguson et. al. reported the discovery of AZ505 and the crystal structure of Smyd2 in complex with AZ505 (Structure 19, 1262-1273, Sep. 7, 2011). The SGC in collaboration with Ely Lilly and Company published the discovery of the Smyd2 inhibitor LLY-507. Inhibitors showing in vivo activity have not been reported to date. Accordingly, it would be desirable to provide novel compounds having prophylactic and therapeutic properties. Part DETAILED DESCRIPTION OF THE INVENTION: It is therefore an object of the present invention to provide compounds and pharmaceutical compositions comprising these compounds as SMYD2 protein inhibitors for prophylactic and therapeutic use for hyperproliferative disorders, in particular for cancer, respectively tumour disorders, for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility. It has now been found that compounds of general formula (I) in which: R1 represents a C1-C6-alkyl group, which is substituted with one substituent selected from —OH, —NH2 or —NHCH3, R2 represents a hydrogen atom, a methyl or an ethyl group, R3 represents a fluorine or a chlorine atom or a methyl group, R4 represents a group selected from: —CF3, —CH2CF3, —OCH3, —OCHF2, —OCF3, —OCH2CF3 or —OCH2CH2N(CH3)2, R5 represents a fluorine or a chlorine atom or a group selected from: —OCH3, —OCF3, X represents CH or N, r represents 0 or 1, as well as their polymorphs, enantiomers, diastereomers, racemates, E/Z-isomers, tautomers, solvates, physiological acceptable salts and solvates of these salts can be prophylactically and therapeutically used in a wide range of diseases, especially in hyperproliferative diseases, and more especially in cancer, respectively tumor treatment. The terms as mentioned in the instant invention are based on the following definitions: Alkyl The term “C1-C6-alkyl” is to be understood as preferably meaning a linear or branched, saturated, monovalent hydrocarbon group having 1, 2, 3, 4, 5 or 6 carbon atoms, e.g. a methyl, ethyl, propyl, butyl, pentyl, hexyl, iso-propyl, iso-butyl, sec-butyl, tert-butyl, iso-pentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neo-pentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 2,3-dimethylbutyl, 1,3-dimethylbutyl, or 1,2-dimethylbutyl group, or an isomer thereof. Particularly, said group has 1, 2, 3 or 4 carbon atoms (“C1-C4-alkyl”), e.g. a methyl, ethyl, propyl, butyl, iso-propyl, iso-butyl, sec-butyl, tert-butyl group, more particularly 1, 2 or 3 carbon atoms (“C1-C3-alkyl”), e.g. a methyl, ethyl, n-propyl- or iso-propyl group. Alkoxy The term “C1-C6-alkoxy” is to be understood as preferably meaning a linear or branched, saturated, monovalent group of formula-O—(C1-C6-alkyl), in which the term “C1-C6-alkyl” is defined above, e.g. a methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, tert-butoxy, sec-butoxy, pentoxy, iso-pentoxy, or n-hexoxy group, or an isomer thereof. The compounds of this invention contain one or more asymmetric centres, depending upon the location and nature of the various substituents desired. Asymmetric carbon atoms may be present in the (R) or (S) configuration. In certain instances, asymmetry may also be present due to restricted rotation about a given bond, for example, the central bond adjoining two substituted aromatic rings of the specified compounds. Substituents on a ring may also be present in either cis or trans form. It is intended that all such configurations are included within the scope of the present invention. Preferred compounds are those which produce the more desirable biological activity. Separated, pure or partially purified isomers and stereoisomers or racemic or diastereomeric mixtures of the compounds of this invention are also included within the scope of the present invention. The purification and the separation of such materials can be accomplished by standard techniques known in the art. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example, by the formation of diastereoisomeric salts using an optically active acid or base or formation of covalent diastereomers. Examples of appropriate acids are tartaric, diacetyltartaric, ditoluoyltartaric and camphorsulfonic acid. Mixtures of diastereoisomers can be separated into their individual diastereomers on the basis of their physical and/or chemical differences by methods known in the art, for example, by chromatography or fractional crystallisation. The optically active bases or acids are then liberated from the separated diastereomeric salts. A different process for separation of optical isomers involves the use of chiral chromatography (e.g., chiral HPLC columns), with or without conventional derivatisation, optimally chosen to maximise the separation of the enantiomers. Suitable chiral HPLC columns are manufactured by Diacel, e.g., Chiracel OD and Chiracel OJ among many others, all routinely selectable. Enzymatic separations, with or without derivatisation, are also useful. The optically active compounds of this invention can likewise be obtained by chiral syntheses utilizing optically active starting materials. In order to limit different types of isomers from each other reference is made to IUPAC Rules Section E (Pure Appl Chem 45, 11-30, 1976). The invention also includes all suitable isotopic variations of a compound of the invention. An isotopic variation of a compound of the invention is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually or predominantly found in nature. Examples of isotopes that can be incorporated into a compound of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulphur, fluorine, chlorine, bromine and iodine, such as 2H (deuterium), 3H (tritium), 11C, 13C, 14C, 15N, 17O, 18O, 32P, 33P, 33S, 34S, 35S, 36S, 18F, 36Cl, 82Br, 123I, 124I, 129I and 131I, respectively. Certain isotopic variations of a compound of the invention, for example, those in which one or more radioactive isotopes such as 3H or 14C are incorporated, are useful in drug and/or substrate tissue distribution studies. Tritiated and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements and hence may be preferred in some circumstances. Isotopic variations of a compound of the invention can generally be prepared by conventional procedures known by a person skilled in the art such as by the illustrative methods or by the preparations described in the examples hereafter using appropriate isotopic variations of suitable reagents. The present invention includes all possible stereoisomers of the compounds of the present invention as single stereoisomers, or as any mixture of said stereoisomers, in any ratio. Isolation of a single stereoisomer, e.g. a single enantiomer or a single diastereomer, of a compound of the present invention may be achieved by any suitable state of the art method, such as chromatography, especially chiral chromatography, for example. The cyanoguanidine moiety can formally adopt E- or Z-configuration: It is assumed, that at relevant temperatures, the two isomers are present in a fast equilibrium, and cannot be analytically or preparatively distinguished, as similarly described for N,N,N′,N′-tetramethylcyanoguanidines (C. Gordon McCarty and Donald M. Wieland: Syn-Anti Isomerization Involving the N-Cyanoimino Group; Tetrahedron Letters No. 22, PP. 1787-1790, 1969). Therefore, any representation of the cyanoguanidine used herein represents both isomers. Further, the compounds of the present invention may exist as tautomers. For example, any compound of the present invention which contains a pyrazole moiety as a heteroaryl group for example can exist as a 1H tautomer, or a 2H tautomer, or even a mixture in any amount of the two tautomers, or a triazole moiety for example can exist as a 1H tautomer, a 2H tautomer, or a 4H tautomer, or even a mixture in any amount of said 1H, 2H and 4H tautomers, viz.: The present invention includes all possible tautomers of the compounds of the present invention as single tautomers, or as any mixture of said tautomers, in any ratio. Further, the compounds of the present invention can exist as N-oxides, which are defined in that at least one nitrogen of the compounds of the present invention is oxidised. The present invention includes all such possible N-oxides. The present invention also relates to useful forms of the compounds as disclosed herein, such as metabolites, hydrates, solvates, prodrugs, salts, in particular pharmaceutically acceptable salts, and co-precipitates. The compounds of the present invention can exist as a hydrate, or as a solvate, wherein the compounds of the present invention contain polar solvents, in particular water, methanol or ethanol for example as structural element of the crystal lattice of the compounds. The amount of polar solvents, in particular water, may exist in a stoichiometric or non-stoichiometric ratio. In the case of stoichiometric solvates, e.g. a hydrate, hemi-, (semi-), mono-, sesqui-, di-, tri-, tetra-, penta- etc. solvates or hydrates, respectively, are possible. The present invention includes all such hydrates or solvates. Further, the compounds of the present invention can exist in free form, e.g. as a free base, or as a free acid, or as a zwitterion, or can exist in the form of a salt. Said salt may be any salt, either an organic or inorganic addition salt, particularly any pharmaceutically acceptable organic or inorganic addition salt, customarily used in pharmacy. The term “pharmaceutically acceptable salt” refers to a relatively non-toxic, inorganic or organic acid addition salt of a compound of the present invention. For example, see S. M. Berge, et al. “Pharmaceutical Salts,” J. Pharm. Sci. 1977, 66, 1-19. A suitable pharmaceutically acceptable salt of the compounds of the present invention may be, for example, an acid-addition salt of a compound of the present invention bearing a nitrogen atom, in a chain or in a ring, for example, which is sufficiently basic, such as an acid-addition salt with an inorganic acid, such as hydrochloric, hydrobromic, hydroiodic, sulfuric, bisulfuric, phosphoric, or nitric acid, for example, or with an organic acid, such as formic, acetic, acetoacetic, pyruvic, trifluoroacetic, propionic, butyric, hexanoic, heptanoic, undecanoic, lauric, benzoic, salicylic, 2-(4-hydroxybenzoyl)-benzoic, camphoric, cinnamic, cyclopentanepropionic, digluconic, 3-hydroxy-2-naphthoic, nicotinic, pamoic, pectinic, persulfuric, 3-phenylpropionic, picric, pivalic, 2-hydroxyethanesulfonate, itaconic, sulfamic, trifluoromethanesulfonic, dodecylsulfuric, ethansulfonic, benzenesulfonic, para-toluenesulfonic, methansulfonic, 2-naphthalenesulfonic, naphthalinedisulfonic, camphorsulfonic acid, citric, tartaric, stearic, lactic, oxalic, malonic, succinic, malic, adipic, alginic, maleic, fumaric, D-gluconic, mandelic, ascorbic, glucoheptanoic, glycerophosphoric, aspartic, sulfosalicylic, hemisulfuric, or thiocyanic acid, for example. Further, another suitably pharmaceutically acceptable salt of a compound of the present invention which is sufficiently acidic, is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically acceptable cation, for example a salt with N-methyl-glucamine, dimethyl-glucamine, ethyl-glucamine, lysine, dicyclohexylamine, 1,6-hexadiamine, ethanolamine, glucosamine, sarcosine, serinol, tris-hydroxy-methyl-aminomethane, aminopropandiol, sovak-base, 1-amino-2,3,4-butantriol. Additionally, basic nitrogen containing groups may be quaternised with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, and dibutyl sulfate; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others. Those skilled in the art will further recognise that acid addition salts of the claimed compounds may be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods. Alternatively, alkali and alkaline earth metal salts of acidic compounds of the invention are prepared by reacting the compounds of the invention with the appropriate base via a variety of known methods. The present invention includes all possible salts of the compounds of the present invention as single salts, or as any mixture of said salts, in any ratio. Furthermore, the present invention includes all possible crystalline forms, or polymorphs, of the compounds of the present invention, either as single polymorphs, or as a mixture of more than one polymorphs, in any ratio. Of particular interest are those compounds of general formula (I), in which R1 represents a group selected from: —CH2—OH, —CH(OH)—CH3, —C(CH3)2—OH, —CH2—NH2, —CH(CH3)—NH2, —CH2—CH2—NH2 or —CH2—CH2—CH2—NH2, R2 represents a hydrogen atom, a methyl or an ethyl group, R3 represents a fluorine or a chlorine atom or a methyl group, R4 represents a group selected from: —CF3, —CH2CF3, —OCH3, —OCHF2, —OCF3 or —OCH2CH2N(CH3)2, R5 represents a fluorine or a chlorine atom or a group selected from: —OCH3, —OCF3, X represents CH or N, r represents 0 or 1, as well as their polymorphs, enantiomers, diastereomers, racemates, E/Z-isomers, tautomers, solvates, physiological acceptable salts and solvates of these salts. It is to be understood that the present invention relates to any sub-combination within any embodiment or aspect of the present invention of compounds of general formula (I), above. In another embodiment, the present invention relates to compounds of the general formula (I), above, in which: R1 represents a C1-C3-alkyl group, which is substituted with one substituent selected from a hydroxy or an amino group. In another embodiment, the present invention relates to compounds of the general formula (I), above, in which: R2 represents a hydrogen atom, a methyl or an ethyl group. In another embodiment, the present invention relates to compounds of the general formula (I), above, in which: R2 represents a hydrogen atom or a methyl group. In another embodiment, the present invention relates to compounds of the general formula (I), above, in which: R2 represents a hydrogen atom. In another embodiment, the present invention relates to compounds of the general formula (I), above, in which: R2 represents a methyl or an ethyl group. In another embodiment, the present invention relates to compounds of the general formula (I), above, in which: R3 represents a fluorine or a chlorine atom or a methyl group. In another embodiment, the present invention relates to compounds of the general formula (I), above, in which: R3 represents a fluorine or a chlorine atom. In another embodiment, the present invention relates to compounds of the general formula (I), above, in which: R3 represents a fluorine atom. In another embodiment, the present invention relates to compounds of the general formula (I), above, in which: R3 represents a chlorine atom. In another embodiment, the present invention relates to compounds of the general formula (I), above, in which: R4 represents a group selected from: —CF3, —CH2CF3, —OCH3, —OCHF2, —OCF3 or —OCH2CH2N(CH3)2. In another embodiment, the present invention relates to compounds of the general formula (I), above, in which: R4 represents a group selected from: —CF3, —CH2CF3, —OCH3, —OCHF2 or —OCF3. In another embodiment, the present invention relates to compounds of the general formula (I), above, in which: R5 represents a fluorine or a chlorine atom or a group selected from: —OCH3, —OCF3, In another embodiment, the present invention relates to compounds of the general formula (I), above, in which: R5 represents a fluorine or a chlorine atom. In another embodiment, the present invention relates to compounds of the general formula (I), above, in which: R5 represents a group selected from: —OCH3, —OCF3, In another embodiment, the present invention relates to compounds of the general formula (I), above, in which: X represents CH or N. In another embodiment, the present invention relates to compounds of the general formula (I), above, in which: X represents CH. In another embodiment, the present invention relates to compounds of the general formula (I), above, in which: X represents N. In another embodiment, the present invention relates to compounds of the general formula (I), above, in which: r represents 0 or 1. In another embodiment, the present invention relates to compounds of the general formula (I), above, in which: r represents 0. In another embodiment, the present invention relates to compounds of the general formula (I), above, in which: r represents 1. In a preferred embodiment, the present invention relates to compounds of general formula (I), above, in which: R1 represents a group selected from: —CH2—OH, —CH(OH)—CH3, —C(CH3)2—OH, —CH2—NH2, —CH(CH3)—NH2, —CH2—CH2—NH2 or —CH2—CH2—CH2—NH2. Of selected interest are those compounds of general formula (I): (2S)—N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-2-hydroxypropanamide (1:1 mixture of diastereomers); Rac-N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-2-hydroxy-N-methylacetamide; Rac-N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethylglycinamide; Rac-N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 1; N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 2; Rac-N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-2-hydroxy-2-methylpropanamide; N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-2-hydroxy-2-methylpropanamide Isomer 1; N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-2-hydroxy-2-methylpropanamide Isomer 2; Rac-N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-beta-alaninamide; N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-D-alaninamide (1:1 mixture of diastereomers); N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-D-alaninamide Isomer 1; N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-D-alaninamide Isomer 2; (2S)—N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxypropanamide (1:1 mixture of diastereomers); (2R)—N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxypropanamide (1:1 mixture of diastereomers); Rac-4-amino-N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethylbutanamide; 4-amino-N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethylbutanamide Isomer 1; 4-amino-N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethylbutanamide Isomer 2; Rac-N-[1-{N-[4-chloro-3-(difluoromethoxy)phenyl]-N′-cyanocarbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[1-{N-[4-chloro-3-(difluoromethoxy)phenyl]-N′-cyanocarbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 1; N-[1-{N-[4-chloro-3-(difluoromethoxy)phenyl]-N′-cyanocarbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 2; Rac-N-[1-{N′-cyano-N-[2-fluoro-3-(trifluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[1-{N′-cyano-N-[2-fluoro-3-(trifluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 1; N-[1-{N′-cyano-N-[2-fluoro-3-(trifluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 2; Rac-N-[1-{N′-cyano-N-[3-(trifluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[1-{N′-cyano-N-[3-(trifluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 1; N-[1-{N′-cyano-N-[3-(trifluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 2; Rac-N-[1-{N′-cyano-N-[4-fluoro-3-(trifluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; Rac-N-{1-[N′-cyano-N-(3-methoxyphenyl)carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl}-N-ethyl-2-hydroxyacetamide; N-{1-[N′-cyano-N-(3-methoxyphenyl)carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl}-N-ethyl-2-hydroxyacetamide Isomer 1; N-{1-[N′-cyano-N-(3-methoxyphenyl)carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl}-N-ethyl-2-hydroxyacetamide Isomer 2; Rac-N-[1-(N′-cyano-N-{3-[2-(dimethylamino)ethoxy]phenyl}carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[1-(N′-cyano-N-{3-[2-(dimethylamino)ethoxy]phenyl}carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 1; N-[1-(N′-cyano-N-{3-[2-(dimethylamino)ethoxy]phenyl}carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 2; Rac-N-[1-(N′-cyano-N-{3-[2-(dimethylamino)ethoxy]phenyl}carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethylglycinamide; Rac-N-[1-{N′-cyano-N-[5-(difluoromethoxy)-2-methoxyphenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[1-{N′-cyano-N-[5-(difluoromethoxy)-2-methoxyphenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 1; N-[1-{N′-cyano-N-[5-(difluoromethoxy)-2-methoxyphenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 2; Rac-N-[1-{N′-cyano-N-[2-methoxy-5-(trifluoromethyl)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[1-{N′-cyano-N-[2-methoxy-5-(trifluoromethyl)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 1; N-[1-{N′-cyano-N-[2-methoxy-5-(trifluoromethyl)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 2; Rac-N-[1-{N′-cyano-N-[6-(difluoromethoxy)pyridin-2-yl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[1-{N′-cyano-N-[6-(difluoromethoxy)pyridin-2-yl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 1; N-[1-{N′-cyano-N-[6-(difluoromethoxy)pyridin-2-yl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 2; Rac-N-[1-{N′-cyano-N-[3-(2,2,2-trifluoroethyl)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[1-{N′-cyano-N-[3-(2,2,2-trifluoroethyl)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 1; N-[1-{N′-cyano-N-[3-(2,2,2-trifluoroethyl)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 2; Rac-N-[1-{N′-cyano-N-[3-(difluoromethoxy)-4-fluorophenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; Rac-N-[1-{N′-cyano-N-[3-(difluoromethoxy)-2-fluorophenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; Rac-N-[1-{N′-cyano-N-[3-(difluoromethoxy)-5-fluorophenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[1-{N′-cyano-N-[3-(difluoromethoxy)-5-fluorophenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 1; N-[1-{N′-cyano-N-[3-(difluoromethoxy)-5-fluorophenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 2; Rac-N-[1-{N′-cyano-N-[3-fluoro-5-(trifluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[1-{N′-cyano-N-[3-fluoro-5-(trifluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 1; N-[1-{N′-cyano-N-[3-fluoro-5-(trifluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 2; Rac-N-[1-{N′-cyano-N-[2-methoxy-5-(trifluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; Rac-N-[1-{N′-cyano-N-[2-(pyrrolidin-1-ylmethyl)-5-(trifluoromethyl)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[1-{N′-cyano-N-[2-(pyrrolidin-1-ylmethyl)-5-(trifluoromethyl)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 1; N-[1-{N′-cyano-N-[2-(pyrrolidin-1-ylmethyl)-5-(trifluoromethyl)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 2; Rac-N-[1-{N′-cyano-N-[2-(trifluoromethoxy)-5-(trifluoromethyl)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; Rac-N-[1-(N′-cyano-N-{5-(difluoromethoxy)-2-[3-(dimethylamino)propoxy]phenyl}-carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; Rac-N-[1-(N′-cyano-N-{2-[2-(pyrrolidin-1-yl)ethoxy]-5-(trifluoromethyl)phenyl}carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; Rac-N-[1-(N′-cyano-N-{2-[(1-methylpiperidin-4-yl)oxy]-5-(trifluoromethyl)phenyl}-carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; Rac-N-[1-(N′-cyano-N-{2-[(1-methylpiperidin-4-yl)oxy]-5-(trifluoromethyl)phenyl}-carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; Rac-N-[3-(4-chloro-3-methylphenyl)-1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]-carbamimidoyl}-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[3-(4-chloro-3-methylphenyl)-1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 1; N-[3-(4-chloro-3-methylphenyl)-1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 2; N-[3-(4-chloro-3-methylphenyl)-1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-L-alaninamide (1:1 mixture of diastereomers); N-[3-(4-chloro-3-methylphenyl)-1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-L-alaninamide Isomer 1; N-[3-(4-chloro-3-methylphenyl)-1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-L-alaninamide Isomer 2 and Rac-N-[3-(4-chloro-3-fluorophenyl)-1-{N′-cyano-N-[3-(trifluoromethoxy)phenyl]-carbamimidoyl}-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; as well as their polymorphs, enantiomers, diastereomers, racemates, E/Z isomers, tautomers, solvates, physiological acceptable salts and solvates of these salts. Of selected interest are those compounds of general formula (I): (2S)—N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-2-hydroxypropanamide (1:1 mixture of diastereomers); Rac-N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-2-hydroxy-N-methylacetamide; Rac-N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethylglycinamide; Rac-N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 1; N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 2; Rac-N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-2-hydroxy-2-methylpropanamide; N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-2-hydroxy-2-methylpropanamide Isomer 1; N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-2-hydroxy-2-methylpropanamide Isomer 2; Rac-N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-beta-alaninamide; N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-D-alaninamide (1:1 mixture of diastereomers); N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-D-alaninamide Isomer 1; N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-D-alaninamide Isomer 2; (2S)—N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxypropanamide (1:1 mixture of diastereomers); (2R)—N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxypropanamide (1:1 mixture of diastereomers); Rac-4-amino-N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethylbutanamide; 4-amino-N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethylbutanamide Isomer 1; 4-amino-N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethylbutanamide Isomer 2; Rac-N-[1-{N-[4-chloro-3-(difluoromethoxy)phenyl]-N′-cyanocarbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[1-{N-[4-chloro-3-(difluoromethoxy)phenyl]-N′-cyanocarbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 1; N-[1-{N-[4-chloro-3-(difluoromethoxy)phenyl]-N′-cyanocarbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 2; Rac-N-[1-{N′-cyano-N-[2-fluoro-3-(trifluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[1-{N′-cyano-N-[2-fluoro-3-(trifluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 1; N-[1-{N′-cyano-N-[2-fluoro-3-(trifluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 2; Rac-N-[1-{N′-cyano-N-[3-(trifluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[1-{N′-cyano-N-[3-(trifluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 1; N-[1-{N′-cyano-N-[3-(trifluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 2; Rac-N-[1-{N′-cyano-N-[4-fluoro-3-(trifluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; Rac-N-{1-[N′-cyano-N-(3-methoxyphenyl)carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl}-N-ethyl-2-hydroxyacetamide; N-{1-[N′-cyano-N-(3-methoxyphenyl)carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl}-N-ethyl-2-hydroxyacetamide Isomer 1; N-{1-[N′-cyano-N-(3-methoxyphenyl)carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl}-N-ethyl-2-hydroxyacetamide Isomer 2; Rac-N-[1-(N′-cyano-N-{3-[2-(dimethylamino)ethoxy]phenyl}carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[1-(N′-cyano-N-{3-[2-(dimethylamino)ethoxy]phenyl}carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 1; N-[1-(N′-cyano-N-{3-[2-(dimethylamino)ethoxy]phenyl}carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 2; Rac-N-[1-(N′-cyano-N-{3-[2-(dimethylamino)ethoxy]phenyl}carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethylglycinamide; Rac-N-[1-{N′-cyano-N-[5-(difluoromethoxy)-2-methoxyphenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[1-{N′-cyano-N-[5-(difluoromethoxy)-2-methoxyphenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 1; N-[1-{N′-cyano-N-[5-(difluoromethoxy)-2-methoxyphenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 2; Rac-N-[1-{N′-cyano-N-[2-methoxy-5-(trifluoromethyl)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[1-{N′-cyano-N-[2-methoxy-5-(trifluoromethyl)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 1; N-[1-{N′-cyano-N-[2-methoxy-5-(trifluoromethyl)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 2; Rac-N-[1-{N′-cyano-N-[6-(difluoromethoxy)pyridin-2-yl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[1-{N′-cyano-N-[6-(difluoromethoxy)pyridin-2-yl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 1; N-[1-{N′-cyano-N-[6-(difluoromethoxy)pyridin-2-yl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 2; Rac-N-[1-{N′-cyano-N-[3-(2,2,2-trifluoroethyl)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[1-{N′-cyano-N-[3-(2,2,2-trifluoroethyl)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 1; N-[1-{N′-cyano-N-[3-(2,2,2-trifluoroethyl)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 2; Rac-N-[1-{N′-cyano-N-[3-(difluoromethoxy)-4-fluorophenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; Rac-N-[1-{N′-cyano-N-[3-(difluoromethoxy)-2-fluorophenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; Rac-N-[1-{N′-cyano-N-[3-(difluoromethoxy)-5-fluorophenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[1-{N′-cyano-N-[3-(difluoromethoxy)-5-fluorophenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 1; N-[1-{N′-cyano-N-[3-(difluoromethoxy)-5-fluorophenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 2; Rac-N-[1-{N′-cyano-N-[3-fluoro-5-(trifluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[1-{N′-cyano-N-[3-fluoro-5-(trifluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 1; N-[1-{N′-cyano-N-[3-fluoro-5-(trifluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 2; Rac-N-[1-{N′-cyano-N-[2-methoxy-5-(trifluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; Rac-N-[1-{N′-cyano-N-[2-(pyrrolidin-1-ylmethyl)-5-(trifluoromethyl)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[1-{N′-cyano-N-[2-(pyrrolidin-1-ylmethyl)-5-(trifluoromethyl)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 1; N-[1-{N′-cyano-N-[2-(pyrrolidin-1-ylmethyl)-5-(trifluoromethyl)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 2; Rac-N-[1-{N′-cyano-N-[2-(trifluoromethoxy)-5-(trifluoromethyl)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; Rac-N-[1-(N′-cyano-N-{5-(difluoromethoxy)-2-[3-(dimethylamino)propoxy]phenyl}-carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; Rac-N-[1-(N′-cyano-N-{2-[2-(pyrrolidin-1-yl)ethoxy]-5-(trifluoromethyl)phenyl}carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; Rac-N-[1-(N′-cyano-N-{2-[(1-methylpiperidin-4-yl)oxy]-5-(trifluoromethyl)phenyl}-carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; Rac-N-[1-(N′-cyano-N-{2-[(1-methylpiperidin-4-yl)oxy]-5-(trifluoromethyl)phenyl}-carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; Rac-N-[3-(4-chloro-3-methylphenyl)-1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]-carbamimidoyl}-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[3-(4-chloro-3-methylphenyl)-1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 1; N-[3-(4-chloro-3-methylphenyl)-1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Isomer 2; N-[3-(4-chloro-3-methylphenyl)-1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-L-alaninamide (1:1 mixture of diastereomers); N-[3-(4-chloro-3-methylphenyl)-1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-L-alaninamide Isomer 1; N-[3-(4-chloro-3-methylphenyl)-1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-L-alaninamide Isomer 2 Rac-N-[3-(4-chloro-3-fluorophenyl)-1-{N′-cyano-N-[3-(trifluoromethoxy)phenyl]-carbamimidoyl}-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; Rac-N-[3-(4-chloro-3-methylphenyl)-1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-N2-methylglycinamide N-[3-(4-chloro-3-methylphenyl)-1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-N2-methylglycinamide Isomer 1 N-[3-(4-chloro-3-methylphenyl)-1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-N2-methylglycinamide Isomer 2 N-[3-(4-chloro-3-methylphenyl)-1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-N2-methyl-D-alaninamide Rac-N-[1-{N′-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-3-methyl-D-isovalinamide N-[1-{N′-Cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-3-methyl-D-isovalinamide Isomer 1 N-[1-{N′-Cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-3-methyl-D-isovalinamide Isomer 2 N-[1-{N′-cyano-N-[3-(trifluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-D-leucinamide N-[1-{N′-Cyano-N-[2-fluoro-3-(trifluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-D-valinamide and N-[1-{N′-Cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-D-valinamide as well as their polymorphs, enantiomers, diastereomers, racemates, E/Z isomers, tautomers, solvates, physiological acceptable salts and solvates of these salts. The compounds of general formula (I) can be used for the prophylactic and therapeutic treatment in hyperproliferative disorders, especially in cancer, respectively tumour disorders. The compounds of general formula (I) can be used as SMYD2 inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and control of male fertility. The instant invention further relates the production of a medicament comprising a compound of general formula (I). Said medicament can be used prophylactically and therapeutically in a human or in another mammal. The present invention moreover also includes prodrugs of the compounds according to the invention. The term “prodrugs” here designates compounds which themselves can be biologically active or inactive, but are converted (for example metabolically or hydrolytically) into compounds according to the invention during their dwell time in the body. The compounds according to the invention can act systemically and/or locally. For this purpose, they can be administered in a suitable manner, such as, for example, orally, parenterally, pulmonarily, nasally, sublingually, lingually, buccally, rectally, dermally, transdermally, conjunctivally, otically, as or as an implant or stent. For these administration routes, the compounds according to the invention can be administered in suitable administration forms. Suitable for oral administration are administration forms working according to the prior art, which release the compounds according to the invention rapidly and/or in modified form and comprise the compounds according to the invention in crystalline and/or amorphized and/or dissolved form, such as, for example, tablets (non-coated or coated tablets, for example coated with enteric, slowly dissolving or insoluble coats which control the release of the compound according to the invention), tablets which decompose rapidly in the oral cavity or films/wafers, films/lyophylizates, capsules (for example hard gelatin capsules or soft gelatin capsules), sugar-coated tablets, granules, pellets, powders, emulsions, suspensions, aerosols or solutions. Parenteral administration can take place with circumvention of an absorption step (for example intravenous, intraarterial, intracardiac, intraspinal or intralumbar) or with involvement of an absorption (for example intramuscular, subcutaneous, intracutaneous, percutaneous or intraperitoneal). For parenteral administration, suitable administration forms are, inter alia, injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilizates or sterile powders. Suitable for the other administration routes are, for example, pharmaceutical forms for inhalation (inter alia powder inhalers, nebulizers), nasal drops, nasal solutions, nasal sprays; tablets, films/wafers or capsules to be applied lingually, sublingually or buccally, suppositories, ear or eye preparations, vaginal capsules, aqueous suspensions (lotions, shake lotions), lipophilic suspensions, ointments, creams, transdermal therapeutic systems (such as, for example, patches), milk, pastes, foams, dusting powders, implants or stents. The compounds according to the invention can be converted into the administration forms mentioned. This may take place in a manner known per se by mixing with inert non-toxic, pharmaceutically acceptable auxiliaries. These auxiliaries include, inter alia, carriers (for example microcrystalline cellulose, lactose, mannitol), solvents (for example liquid polyethylene glycols), emulsifiers and dispersants or wetting agents (for example sodium dodecylsulphate, polyoxysorbitan oleate), binders (for example polyvinylpyrrolidone), synthetic and natural polymers (for example albumin), stabilizers (e.g. antioxidants such as, for example, ascorbic acid), colorants (e.g. inorganic pigments such as, for example, iron oxides) and taste and/or odour corrigents. The present invention furthermore provides medicaments comprising the compounds according to the invention, usually together with one or more inert non-toxic, pharmaceutically suitable auxiliaries, and their use for the purposes mentioned. Formulation of the compounds according to the invention to give pharmaceutical products takes place in a manner known per se by converting the active compound(s) with the excipients customary in pharmaceutical technology into the desired administration form. Auxiliaries which can be employed in this connection are, for example, carrier substances, fillers, disintegrants, binders, humectants, lubricants, absorbents and adsorbents, diluents, solvents, cosolvents, emulsifiers, solubilizers, masking flavours, colorants, preservatives, stabilizers, wetting agents, salts to alter the osmotic pressure or buffers. Reference should be made in this connection to Remington's Pharmaceutical Science, 15th ed. Mack Publishing Company, East Pennsylvania (1980). The pharmaceutical formulations may be in solid form, for example as tablets, coated tablets, pills, suppositories, capsules, transdermal systems or in semisolid form, for example as ointments, creams, gels, suppositories, emulsions or in liquid form, for example as solutions, tinctures, suspensions or emulsions. Auxiliaries in the context of the invention may be, for example, salts, saccharides (mono-, di-, tri-, oligo-, and/or polysaccharides), proteins, amino acids, peptides, fats, waxes, oils, hydrocarbons and derivatives thereof, where the auxiliaries may be of natural origin or may be obtained by synthesis or partial synthesis. Suitable for oral or peroral administration are in particular tablets, coated tablets, capsules, pills, powders, granules, pastilles, suspensions, emulsions or solutions. Suitable for parenteral administration are in particular suspensions, emulsions and especially solutions. Dose and Administration Based upon standard laboratory techniques known to evaluate compounds useful for the treatment of hyper-proliferative disorders and angiogenic disorders, by standard toxicity tests and by standard pharmacological assays for the determination of treatment of the conditions identified in mammals, and by comparison of these results with the results of known medicaments that are used to treat these conditions, the effective dosage of the compounds of this invention can readily be determined for treatment of each desired indication. The amount of the active ingredient to be administered in the treatment of one of these conditions can vary widely according to such considerations as the particular compound and dosage unit employed, the mode of administration, the period of treatment, the age and sex of the patient treated, and the nature and extent of the condition treated. The total amount of the active ingredient to be administered will generally range from about 0.001 mg/kg to about 200 mg/kg body weight per day, and preferably from about 0.01 mg/kg to about 20 mg/kg body weight per day. Clinically useful dosing schedules will range from one to three times a day dosing to once every four weeks dosing. In addition, “drug holidays” in which a patient is not dosed with a drug for a certain period of time, may be beneficial to the overall balance between pharmacological effect and tolerability. A unit dosage may contain from about 0.5 mg to about 1500 mg of active ingredient, and can be administered one or more times per day or less than once a day. The average daily dosage for administration by injection, including intravenous, intramuscular, subcutaneous and parenteral injections, and use of infusion techniques will preferably be from 0.01 to 200 mg/kg of total body weight. The average daily rectal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight. The average daily vaginal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight. The average daily topical dosage regimen will preferably be from 0.1 to 200 mg administered between one to four times daily. The transdermal concentration will preferably be that required to maintain a daily dose of from 0.01 to 200 mg/kg. The average daily inhalation dosage regimen will preferably be from 0.01 to 100 mg/kg of total body weight. Of course the specific initial and continuing dosage regimen for each patient will vary according to the nature and severity of the condition as determined by the attending diagnostician, the activity of the specific compound employed, the age and general condition of the patient, time of administration, route of administration, rate of excretion of the drug, drug combinations, and the like. The desired mode of treatment and number of doses of a compound of the present invention or a pharmaceutically acceptable salt or ester or composition thereof can be ascertained by those skilled in the art using conventional treatment tests. The present invention further relates to the use of the compounds according to the invention. The compounds according to the invention can be used for the prophylaxis and therapy of human disorders, in particular tumour disorders. The compounds according to the invention can be used in particular for inhibiting or reducing cell proliferation and/or cell division and/or to induce apoptosis. The compounds according to the invention are suitable in particular for the treatment of hyper-proliferative disorders such as, for example, psoriasis, keloids and other skin hyperplasias, benign prostate hyperplasias (BPH), solid tumours and haematological tumours. Solid tumours which can be treated in accordance with the invention are, for example, tumours of the breast, the respiratory tract, the brain, the reproductive organs, the gastrointestinal tract, the urogenital tract, the eye, the liver, the skin, the head and the neck, the thyroid gland, the parathyroid gland, the bones and the connective tissue and metastases of these tumours. Haematological tumours which can be treated are, for example, multiple myelomas, lymphomas or leukaemias. Breast tumours which can be treated are, for example: breast carcinomas with positive hormone receptor status breast carcinomas with negative hormone receptor status Her-2 positive breast carcinomas hormone receptor and Her-2 negative breast carcinomas BRCA-associated breast carcinomas inflammatory breast carcinomas. Tumours of the respiratory tract which can be treated are, for example, non-small-cell bronchial carcinomas such as squamous-cell carcinoma, adenocarcinoma, large-cell carcinoma and small-cell bronchial carcinomas. Tumours of the brain which can be treated are, for example, gliomas, glioblastomas, astrocytomas, meningiomas and medulloblastomas. Tumours of the male reproductive organs which can be treated are, for example: prostate carcinomas, malignant tumours of the epididymis, malignant testicular tumours and penis carcinomas. Tumours of the female reproductive organs which can be treated are, for example: endometrial carcinomas cervix carcinomas ovarial carcinomas vaginal carcinomas vulvar carcinomas Tumours of the gastrointestinal tract which can be treated are, for example: colorectal carcinomas anal carcinomas stomach carcinomas pancreas carcinomas oesophagus carcinomas gall bladder carcinomas carcinomas of the small intestine salivary gland carcinomas neuroendocrine tumours gastrointestinal stroma tumours Tumours of the urogenital tract which can be treated are, for example: urinary bladder carcinomas kidney cell carcinomas carcinomas of the renal pelvis and lower urinary tract Tumours of the eye which can be treated are, for example: retinoblastomas intraocular melanomas Tumours of the liver which can be treated are, for example: hepatocellular carcinomas cholangiocellular carcinomas Tumours of the skin which can be treated are, for example: malignant melanomas basaliomas spinaliomas Kaposi sarcomas Merkel cell carcinomas Tumours of the head and neck which can be treated are, for example: larynx carcinomas carcinomas of the pharynx and the oral cavity carcinomas of midline structures (e.g. NMC, C. A. French, Annu. Rev. Pathol. 2012, 7:247-265) Sarcomas which can be treated are, for example: soft tissue sarcomas osteosarcomas Lymphomas which can be treated are, for example: non-Hodgkin lymphomas Hodgkin lymphomas cutaneous lymphomas lymphomas of the central nervous system AIDS-associated lymphomas Leukaemias which can be treated are, for example: acute myeloid leukaemias chronic myeloid leukaemias acute lymphatic leukaemias chronic lymphatic leukaemias hairy cell leukaemias Advantageously, the compounds according to the invention can be used for the prophylaxis and/or therapy of leukaemias, in particular acute myeloid leukaemias, prostate carcinomas, in particular androgen receptor-positive prostate carcinomas, cervix carcinomas, breast carcinomas, in particular of hormone receptor negative, hormone receptor positive or BRCA-associated breast carcinomas, pancreas carcinomas, kidney cell carcinomas, hepatocellular carcinomas, melanomas and other skin tumours, non-small-cell bronchial carcinomas, endometrial carcinomas and colorectal carcinomas. Particularly advantageously, the compounds according to the invention can be employed for the prophylaxis and/or therapy of leukaemias, in particular acute myeloid leukaemias, prostate carcinomas, in particular androgen receptor-positive prostate carcinomas, breast carcinomas, in particular oestrogen receptor alpha-negative breast carcinomas, melanomas or multiple myelomas. The compounds according to the invention are also suitable for the prophylaxis and/or therapy of benign hyperproliferative diseases such as endometriosis, leiomyoma and benign prostate hyperplasia. The compounds according to the invention are also suitable for controlling male fertility. The compounds according to the invention are also suitable for the prophylaxis and/or therapy of systemic inflammatory diseases, in particular LPS-induced endotoxic shock and/or bacteria-induced sepsis. The compounds according to the invention are also suitable for the prophylaxis and/or therapy of inflammatory or autoimmune disorders such as: pulmonary disorders associated with inflammatory, allergic or proliferative processes: chronic obstructive pulmonary disorders of any origin, especially bronchial asthma; bronchitis of varying origin; all types of restrictive pulmonary disorders, especially allergic alveolitis; all types of pulmonary oedema, especially toxic pulmonary oedema; sarcoidoses and granulomatoses, especially Boeck's disease rheumatic disorders/autoimmune diseases/joint disorders associated with inflammatory, allergic or proliferative processes: all types of rheumatic disorders, especially rheumatoid arthritis, acute rheumatic fever, polymyalgia rheumatica; reactive arthritis; inflammatory soft tissue disorders of other origin; arthritic symptoms associated with degenerative joint disorders (arthroses); traumatic arthritides; collagenoses of any origin, e.g. systemic lupus erythematosus, scleroderma, polymyositis, dermatomyositis, Sjögren's syndrome, Still's syndrome, Felty's syndrome allergies associated with inflammatory or proliferative processes: all types of allergic reactions, e.g. angioedema, hay fever, insect bite, allergic reactions to drugs, blood derivatives, contrast media etc., anaphylactic shock, urticaria, contact dermatitis vessel inflammations (vasculitides): panarterilitis nodosa, arterilitis temporalis, erythema nodosum dermatological disorders associated with inflammatory, allergic or proliferative processes: atopic dermatitis; psoriasis; pityriasis rubra pilaris; erythematous disorders induced by various noxae, e.g. radiation, chemicals, burns etc.; bullous dermatoses; lichenoid disorders; pruritus; seborrheic eczema; rosacea; pemphigus vulgaris; erythema exsudativum multiforme; balanitis; vulvitis; hair loss such as alopecia areata; cutaneous T-cell lymphomas renal disorders associated with inflammatory, allergic or proliferative processes: nephrotic syndrome; all nephritides hepatic disorders associated with inflammatory, allergic or proliferative processes: acute liver cell necrosis; acute hepatitis of varying origin, e.g. viral, toxic, drug-induced; chronic aggressive and/or chronic intermittent hepatitis gastrointestinal disorders associated with inflammatory, allergic or proliferative processes: regional enteritis (Crohn's disease); ulcerative colitis; gastritis; reflux oesophagitis; gastroenteritides of other origin, e.g. indigenous sprue proctological disorders associated with inflammatory, allergic or proliferative processes: anal eczema; fissures; haemorrhoids; idiopatic proctitis ocular disorders associated with inflammatory, allergic or proliferative processes: allergic keratitis, uveitis, iritis; conjunctivitis; blepharitis; optic neuritis; chlorioditis; sympathetic ophthalmia ear-nose-throat disorders associated with inflammatory, allergic or proliferative processes: allergic rhinitis, hay fever; otitis externa, e.g. caused by contact eczema, infection etc.; otitis media neurological disorders associated with inflammatory, allergic or proliferative processes: cerebral oedema, especially tumour-induced cerebral oedema; multiple sclerosis; acute encephalomyelitis; meningitis; various types of spasms, e.g. West syndrome haematological disorders associated with inflammatory, allergic or proliferative processes: acquired haemolytic anaemia; idiopathic thrombocytopenia tumour disorders associated with inflammatory, allergic or proliferative processes: acute lymphatic leukaemia; malignant lymphomas; lymphogranulomatoses; lymphosarcomas; extensive metastasization, especially in cases of breast, bronchial and prostate carcinomas endocrine disorders associated with inflammatory, allergic or proliferative processes: endocrine orbitopathy; thyreotoxic crisis; de Quervain thyroiditis; Hashimoto thyroiditis; Basedow's disease organ and tissue transplantations, graft-versus-host disease severe states of shock, e.g. anaphylactic shock, systemic inflammatory response syndrome (SIRS) substitution therapy in cases of: congenital primary adrenal insufficiency, e.g. congenital adrenogenital syndrome; acquired primary adrenal insufficiency, e.g. Addison's disease, autoimmune adrenalitis, postinfectious tumours, metastases, etc; congenital secondary adrenal insufficiency, e.g. congenitaler hypopituitarism; acquired secondary adrenal insufficiency, e.g. postinfectious, tumours, etc emesis associated with inflammatory, allergic or proliferative processes, e.g. in combination with a 5-HT3 antagonist for emesis induced by cytostatic drugs pain of inflammatory origin, e.g. lumbago. The inventive compounds can be combined with one or more active compounds. Those compounds that can be combined with the inventive compounds can be, for example, those as follows: The compounds according to the invention are also suitable for the treatment of viral disorders such as, for example, infections caused by papilloma viruses, herpes viruses, Epstein-Barr viruses, hepatitis B or C viruses and human immunodeficiency viruses, including HIV associated kidney diseases. The inventive compounds are also suitable for the treatment of muscle dystrophia, such as fazioskapulo human muscle dystrophia. The compounds according to the invention are also suitable for the treatment of atherosklerosis, dyslipidaemia, hypercholesterolaemia, hypertriglyceridaemia, peripheral vascular disorders, cardiovascular disorders, angina pectoris, ischaemia, stroke, insufficiency of the heart, myocardial infarction, angioplastic restenosis, hypertension, thrombosis, adiposity, endotoxemia. The compounds according to the invention are also suitable for the treatment of neurodegenerative diseases such as, for example, multiple sclerosis, Alzheimer's disease and Parkinson's disease. These disorders are well characterized in man but also exist in other mammals. The present application furthermore provides the compounds according to the invention for use as medicaments, in particular for the prophylaxis and/or therapy of tumour disorders. The present application furthermore provides the compounds according to the invention for the prophylaxis and/or therapy of leukaemias, in particular acute myeloid leukaemias, prostate carcinomas, in particular androgen receptor-positive prostate carcinomas, cervix carcinomas, breast carcinomas, in particular hormone receptor-negative, hormone receptor-positive or BRCA-associated breast carcinomas, pancreas carcinomas, kidney cell carcinomas, hepatocellular carcinomas, melanomas and other skin tumours, non-small-cell bronchial carcinomas, endometrial carcinomas and colorectal carcinomas. The present application furthermore provides the compounds according to the invention for the prophylaxis and/or therapy of leukaemias, in particular acute myeloid leukaemias, prostate carcinomas, in particular androgen receptor-positive prostate carcinomas, breast carcinomas, in particular oestrogen receptor alpha-negative breast carcinomas, melanomas or multiple myelomas. The invention furthermore provides the use of the compounds according to the invention for preparing a medicament. The present application furthermore provides the use of the compounds according to the invention for preparing a medicament for the prophylaxis and/or therapy of tumour disorders. The present application furthermore provides the use of the compounds according to the invention for preparing a medicament for the prophylaxis and/or therapy of leukaemias, in particular acute myeloid leukaemias, prostate carcinomas, in particular androgen receptor-positive prostate carcinomas, cervix carcinomas, breast carcinomas, in particular of hormone receptor-negative, hormone receptor-positive or BRCA-associated breast carcinomas, pancreas carcinomas, kidney cell carcinomas, hepatocellular carcinomas, melanomas and other skin tumours, non-small-cell bronchial carcinomas, endometrial carcinomas and colorectal carcinomas. The present application furthermore provides the use of the compounds according to the invention for preparing a medicament for the prophylaxis and/or therapy of leukaemias, in particular acute myeloid leukaemias, prostate carcinomas, in particular androgen receptor-positive prostate carcinomas, breast carcinomas, in particular oestrogen receptor alpha-negative breast carcinomas, melanomas or multiple myelomas. The present application furthermore provides the use of the compounds according to the invention for the prophylaxis and/or therapy of tumour disorders. The present application furthermore provides the use of the compounds according to the invention for the prophylaxis and/or therapy of leukaemias, in particular acute myeloid leukaemias, prostate carcinomas, in particular androgen receptor-positive prostate carcinomas, cervix carcinomas, breast carcinomas, in particular hormone receptor-negative, hormone receptor-positive or BRCA-associated breast carcinomas, pancreas carcinomas, kidney cell carcinomas, hepatocellular carcinomas, melanomas and other skin tumours, non-small-cell bronchial carcinomas, endometrial carcinomas and colorectal carcinomas. The present application furthermore provides the use of the compounds according to the invention for the prophylaxis and/or therapy of leukaemias, in particular acute myeloid leukaemias, prostate carcinomas, in particular androgen receptor-positive prostate carcinomas, breast carcinomas, in particular oestrogen receptor alpha-negative breast carcinomas, melanomas or multiple myelomas. The present application furthermore provides pharmaceutical formulations in the form of tablets comprising one of the compounds according to the invention for the prophylaxis and/or therapy of leukaemias, in particular acute myeloid leukaemias, prostate carcinomas, in particular androgen receptor-positive prostate carcinomas, cervix carcinomas, breast carcinomas, in particular of hormone receptor-negative, hormone receptor-positive or BRCA-associated breast carcinomas, pancreas carcinomas, kidney cell carcinomas, hepatocellular carcinomas, melanomas and other skin tumours, non-small-cell bronchial carcinomas, endometrial carcinomas and colorectal carcinomas. The present application furthermore provides pharmaceutical formulations in the form of tablets comprising one of the compounds according to the invention for the prophylaxis and/or therapy of leukaemias, in particular acute myeloid leukaemias, prostate carcinomas, in particular androgen receptor-positive prostate carcinomas, breast carcinomas, in particular oestrogen receptor-alpha-negative breast carcinomas, melanomas or multiple myelomas. The instant invention further comprises a pharmaceutical formulation that comprises one or more compounds of general formula (I), alone or in combination with one or more further active compounds. The invention furthermore provides the use of the compounds according to the invention for treating disorders associated with proliferative processes. The invention furthermore provides the use of the compounds according to the invention for treating benign hyperplasias, inflammatory disorders, autoimmune disorders, sepsis, viral infections, vascular disorders and neurodegenerative disorders. The compounds according to the invention can be employed by themselves or, if required, in combination with one or more other pharmacologically active substances, as long as this combination
{'bibliographic_information': "{'country': 'US', 'doc-number': '15534404', 'kind': 'B2', 'date': '20151208', 'invention_title': 'Aryl-cyanoguanidine compounds'}", 'source_file': './grant/2018/ipg180717.xml', 'source_data': 'USPTO-Grant'}